Mechanism of thrombin inhibition by heparin cofactor II in the presence of dermatan sulphates, native or oversulphated, and a heparin-like dextran derivative
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Proteoglycans and glycosaminoglycans research · Carbohydrate Chemistry and Synthesis · Protease and Inhibitor Mechanisms
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (23)
Show source-provided references
1. Activation of heparin cofactor II by dermatan sulfate10.1016/S0021-9258(18)32276-2 ↗
2. Activation of heparin cofactor II by heparin and dermatan sulfate
3. The N-terminal acidic domain of heparin cofactor II mediates the inhibition of α-thrombin in the presence of glycosa-minoglycans10.1016/S0021-9258(18)54913-9 ↗
4. Role of thrombin exosites in inhibition by heparin cofactor II10.1016/S0021-9258(19)50568-3 ↗
5. Binding of heparin or dermatan sulfate to thrombin is essential for the sulfated polysaccharide-accelerated inhibition of thrombin by heparin cofactor II10.1016/0014-5793(87)81140-7 ↗
6. Molecular size of dermatan sulfate oligosaccharides required to bind and activate heparin cofactor II10.1016/S0021-9258(19)84460-5 ↗
7. Glycosamino-glycan-catalyzed inactivation of thrombin by heparin cofactor II: Differences between the dermatan sulfate and heparin catalyzed reactions
8. Thrombin inactivation by heparin cofactor II: Comparison of the uncatalyzed and dermatan sulfate-catalyzed reactions
9. Respective role of antithrombin III and heparin cofactor II in the in-vitro coagulant effect of heparin and of various sulphated polysaccharides10.1111/j.1365-2141.1986.tb02232.x ↗
10. Anticoagulant activity of dermatan polysulfates10.1620/tjem.136.359 ↗
11. Increased sulphation improves the anticoagulant activities of heparan sulphate and dermatan sulphate10.1042/bj2480889 ↗
12. Effects of increased sulfation of dermatan sulfate on its in vitro and in vivo pharmacological properties10.1016/0049-3848(88)90094-1 ↗
13. Influence of the oversulfation method and the degree of sulfation on the anticoagulant properties of dermatan sulfate derivatives10.1016/0049-3848(90)90056-I ↗
14. Interactions of biospecific functional polymers with blood proteins and cells10.1163/156856290X00017 ↗
15. Bioactive specific biomaterials: Present and future10.1351/pac199264111783 ↗
16. Anticoagulant activity of dextran derivatives. Part II: Mechanism of thrombin inactivation10.1016/0142-9612(85)90010-9 ↗
17. Molecular weight dependency of the acquired anticomplementary and anticoagulant activities of specifically substituted dextrans10.1016/0142-9612(87)90111-6 ↗
18. Mechanism of thrombin inhibition by antithrombin and heparin cofactor II in the presence of heparin10.1016/S0142-9612(96)00125-1 ↗
19. Fractionation of low molecular weight heparin species and their interaction with antithrombin10.1016/S0021-9258(17)30159-X ↗
20. Affinity chromatography of sulphated polysaccharides separately fractionated on antithrombin III and heparin cofactor II immobilized on concanavallin A-sepharose10.1016/0378-4347(93)80335-2 ↗
21. Structural differences of dermatan sulfates from different origins10.1016/0008-6215(86)85009-1 ↗
22. Molecular and functional heterogeneity in dermatan sulfate preparations
23. Isolation of dermatan sulfate with high heparin cofactor II-mediated thrombin inhibitory activity from porcine spleen10.1016/0304-4165(87)90198-X ↗